PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › BL-M07D1

Drugs in development · updated 30 October 2026

BL-M07D1: clinical trials and development status

Development codeNot approved in the USNo EMA authorisationEstimated launch Dec 2027 – Oct 2028 (Phuturdex estimate)

As of 30 October 2026 BL-M07D1 is in 20 active clinical trials (recruiting or ongoing, phases I–III) for 14 diseases. The most advanced phase is III.

20Active trials
IIIMost advanced phase
14Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow BL-M07D1 and get an email at every change or safety alert.

Sign in free →

Diseases studied

For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.

DiseaseMost advanced phaseActive trialsReference trial
Biliary tract neoplasmIII2NCT07606599
Colorectal neoplasmIII1NCT07730489
Fallopian tube neoplasmIII1NCT07545460
Ovarian epithelial carcinomaIII1NCT07545460
Breast neoplasmII3NCT07678957
Non-small-cell lung carcinomaI–II1NCT06114511
Endometrial neoplasmI1NCT06293898
Esophageal neoplasmI1NCT06293898
Lung neoplasmI1NCT06293898
MetastasisI1NCT05461768
Ovarian neoplasmI1NCT06293898
Stomach neoplasmI1NCT06293898
Transitional cell carcinomaI1NCT06293898
Uterine cervix neoplasmI1NCT06293898

Everything on BL-M07D1

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch